Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KOOL Cesca Therapeutics	$11.81 -0.4%	$2.78	$2.10 ▼ $7.00	$28.54M	1.07	112,188 shs	23 shs
LUCD Lucid Diagnostics	$1.16 -1.3%	$1.24	$0.72 ▼ $1.80	$124.96M	1.23	694,829 shs	573,949 shs
OBIO Orchestra BioMed	$2.95 +1.0%	$2.96	$2.37 ▼ $8.87	$113.01M	0.61	179,801 shs	14,847 shs
THMO ThermoGenesis		$0.00	$0.00 ▼ $0.60	$1K	1.17	5,900 shs	N/A

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KOOL Cesca Therapeutics	+0.30%	+0.28%	+4.97%	+20.48%	+10.36%
LUCD Lucid Diagnostics	0.00%	+10.38%	-9.30%	+7.34%	+32.92%
OBIO Orchestra BioMed	-3.63%	-0.34%	-5.50%	+2.10%	-65.77%
THMO ThermoGenesis	0.00%	0.00%	0.00%	-66.67%	-99.94%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KOOL Cesca Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	2.5969 of 5 stars	3.6	2.0	0.0	0.0	2.9	1.7	0.6
OBIO Orchestra BioMed	2.9183 of 5 stars	3.6	5.0	0.0	0.0	2.1	1.7	0.0
THMO ThermoGenesis	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KOOL Cesca Therapeutics	0.00	N/A	N/A	N/A
LUCD Lucid Diagnostics	3.20	Buy	$3.55	207.36% Upside
OBIO Orchestra BioMed	3.20	Buy	$14.20	381.36% Upside
THMO ThermoGenesis	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest KOOL, THMO, LUCD, and OBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
6/6/2025	LUCD Lucid Diagnostics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.50 ➝ $7.75
5/15/2025	LUCD Lucid Diagnostics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$2.00 ➝ $2.00
5/14/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
5/13/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/5/2025	OBIO Orchestra BioMed	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $12.00
4/23/2025	OBIO Orchestra BioMed	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/22/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/21/2025	LUCD Lucid Diagnostics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $7.50

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KOOL Cesca Therapeutics	$9.67M	2.95	N/A	N/A	$3.11 per share	3.80
LUCD Lucid Diagnostics	$4.35M	28.73	N/A	N/A	($0.78) per share	-1.48
OBIO Orchestra BioMed	$2.64M	42.81	N/A	N/A	$0.87 per share	3.39
THMO ThermoGenesis	$9.61M	0.00	N/A	N/A	($0.99) per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KOOL Cesca Therapeutics	-$39.72M	-$3.60	N/A	1,181.14	N/A	-98.84%	-77.30%	-37.75%	N/A
LUCD Lucid Diagnostics	-$45.53M	-$1.34	N/A	N/A	N/A	-1,699.86%	N/A	-124.27%	8/11/2025 (Estimated)
OBIO Orchestra BioMed	-$61.02M	-$1.78	N/A	N/A	N/A	-2,297.85%	-189.26%	-93.76%	N/A
THMO ThermoGenesis	-$17.98M	-$5.14	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest KOOL, THMO, LUCD, and OBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2025	Q2 2025	LUCD Lucid Diagnostics	-$0.09	N/A	N/A	N/A	$1.15 million	N/A
5/12/2025	Q1 2025	OBIO Orchestra BioMed	-$0.46	-$0.49	-$0.03	-$0.49	$0.39 million	$0.87 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KOOL Cesca Therapeutics	N/A	0.50%	N/A	N/A	N/A
LUCD Lucid Diagnostics	N/A	N/A	N/A	N/A	N/A
OBIO Orchestra BioMed	N/A	N/A	N/A	N/A	N/A
THMO ThermoGenesis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KOOL Cesca Therapeutics	0.50	1.52	0.91
LUCD Lucid Diagnostics	N/A	0.75	0.74
OBIO Orchestra BioMed	0.85	3.35	3.34
THMO ThermoGenesis	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KOOL Cesca Therapeutics	3.11%
LUCD Lucid Diagnostics	74.01%
OBIO Orchestra BioMed	53.55%
THMO ThermoGenesis	5.78%

Insider Ownership

Company	Insider Ownership
KOOL Cesca Therapeutics	68.90%
LUCD Lucid Diagnostics	6.80%
OBIO Orchestra BioMed	8.10%
THMO ThermoGenesis	78.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KOOL Cesca Therapeutics	53	2.42 million	N/A	Not Optionable
LUCD Lucid Diagnostics	70	108.19 million	100.83 million	No Data
OBIO Orchestra BioMed	4	38.31 million	35.21 million	Not Optionable
THMO ThermoGenesis	40	7.95 million	1.75 million	Not Optionable

KOOL, THMO, LUCD, and OBIO Headlines

Recent News About These Companies

The Ice Water Hack: How Aqua Sculpt Boosts Thermogenesis for Fat Loss

March 10, 2025 | globenewswire.com

Ice Water Hack: How Aqua Sculpt Improves Thermogenesis for Weight Loss

February 20, 2025 | globenewswire.com

North American Morning Briefing: Stock Futures, -2-

September 19, 2024 | morningstar.comM

Is Thermogenesis Holdings Inc Stock (THMO) a Good Investment?

August 8, 2024 | aaii.comA

ThermoGenesis Holdings (OTC:THMO) Stock Quotes, Forecast and News Summary

July 28, 2024 | benzinga.com

ThermoGenesis Holdings (OTC:THMO) Stock, Short Interest Report

July 28, 2024 | benzinga.com

Why Is ThermoGenesis (THMO) Stock Down 37% Today?

June 12, 2024 | investorplace.com

THMO Stock Earnings: ThermoGenesis Holdings Misses EPS, Misses Revenue for Q1 2024

May 17, 2024 | investorplace.com

ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Is About To Turn The Corner

February 27, 2024 | finance.yahoo.com

ThermoGenesis Holdings, Inc.

January 9, 2024 | thestreet.com

ThermoGenesis Holdings Stock (NASDAQ:THMO) Dividends: History, Yield and Dates

December 16, 2023 | benzinga.com

Shareholders Will Probably Hold Off On Increasing ThermoGenesis Holdings, Inc.'s (NASDAQ:THMO) CEO Compensation For The Time Being

December 8, 2023 | finance.yahoo.com

ThermoGenesis Holdings Recent Insider Activity

November 21, 2023 | benzinga.com

ThermoGenesis Holdings, Inc.: ThermoGenesis Holdings Announces Third Quarter 2023 Financial Results and Provides Corporate Update

November 15, 2023 | finanznachrichten.de

ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Q3 2023 Earnings Call Transcript

November 14, 2023 | finance.yahoo.com

ThermoGenesis Holdings Announces Third Quarter 2023 Financial Results and Provides Corporate Update

November 13, 2023 | finance.yahoo.com

ThermoGenesis Q3 Earnings Preview

November 12, 2023 | msn.com

Here's what Wall Street expects from ThermoGenesis's earnings report

November 12, 2023 | markets.businessinsider.com

ThermoGenesis Holdings Inc THMO

November 12, 2023 | morningstar.comM

ThermoGenesis Holdings Earnings Preview

November 10, 2023 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KOOL, THMO, LUCD, and OBIO Company Descriptions

Cesca Therapeutics NASDAQ:KOOL

Cesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. It offers AutoXpress System, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood; Point-of-CareXpress System, a proprietary automated device and companion sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow; CAR-TXpress System, a suite of multi-component automated system that allows the automated manufacturing, expansion, and storage of cellular therapies for immuno-oncology; BioArchive System, an automated cryogenic device for single-cassette based cryo-storage of biological license applications products; and manual bag sets for use in the processing and cryogenic storage of cord blood. The company is also developing autologous stem cell-based therapies that address medical needs for applications in the vascular, cardiology, and orthopedic markets. In addition, it provides cell manufacturing and banking services. The company was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California. Cesca Therapeutics Inc. is a subsidiary of Boyalife (Hong Kong) Limited.

Lucid Diagnostics NASDAQ:LUCD

$1.16 -0.02 (-1.28%)

As of 10:53 AM Eastern

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Orchestra BioMed NASDAQ:OBIO

$2.95 +0.03 (+1.03%)

As of 10:52 AM Eastern

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

ThermoGenesis NASDAQ:THMO

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company's point-of-care applications include XP Point-of-Care System, an automated, fully closed, sterile system that allows for the rapid and automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and PXP-1000 System, an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. Its cell processing products comprise X-Series products for general laboratory use, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The company also provides contract development and manufacturing services for cell and cell-based gene therapies. It markets and sells its medical device products through independent distributors, as well as direct to end-user customers. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time